Is hepatitis B screening (HBsAg and anti‑HBc) required before initiating baricitinib therapy?

Yes, hepatitis B screening is required before starting baricitinib.

All patients must undergo hepatitis B virus testing for HBsAg, anti-HBc, and anti-HBs before initiating baricitinib therapy 1. This is a clear, non-negotiable requirement based on consensus guidelines for JAK inhibitors.

Required Screening Tests

You must order the following three tests:

• HBsAg (Hepatitis B surface antigen)
• Anti-HBc (Hepatitis B core antibody)
• Anti-HBs (Hepatitis B surface antibody)

Clinical Algorithm Based on Results

If HBsAg Positive (Chronic HBV Infection)

• Avoid baricitinib if possible
• If baricitinib is absolutely necessary:
  • Start antiviral prophylaxis (entecavir, tenofovir, or tenofovir alafenamide) before initiating baricitinib
  • Consult hepatology
  • Continue antivirals throughout treatment and for at least 6 months after stopping baricitinib 1, 2

If HBsAg Negative but Anti-HBc Positive (Prior HBV Exposure)

• Order HBV DNA to rule out occult infection
• If HBV DNA positive: Manage as chronic infection (see above)
• If HBV DNA negative:
  • May start baricitinib
  • Monitor HBV DNA and HBsAg regularly during treatment (every 1-3 months per national TNFi guidelines)
  • If either becomes positive during monitoring: stop baricitinib temporarily, consult hepatology, start antivirals, then may resume baricitinib 1

If All Tests Negative

• Proceed with baricitinib without additional HBV precautions

Why This Matters

JAK inhibitors like baricitinib carry moderate risk for HBV reactivation 2. Clinical trial data from baricitinib studies showed that among 215 patients with prior HBV exposure (anti-HBc positive), 4 patients (1.9%) experienced HBV reactivation with DNA levels ≥100 IU/mL 3. While none developed clinical hepatitis in these trials, HBV reactivation can lead to hepatitis flare, hepatic failure, and death in real-world settings—making screening essential for patient safety.

Common Pitfall to Avoid

Do not skip anti-HBc testing. Many clinicians only check HBsAg, but anti-HBc positive/HBsAg negative patients (resolved infection) remain at risk for reactivation with immunosuppression. The 2021 EULAR consensus specifically mandates all three serologic markers for JAK inhibitor screening 1, and the 2025 AGA guidelines strongly recommend hepatitis B testing for all individuals at risk of HBV reactivation 2.